Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2021 1
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
[Oropharyngeal cancer].
Lafond C, Pointreau Y, Debelleix C, Denis F, Calais G, Bourhis J, Thariat J. Lafond C, et al. Among authors: debelleix c. Cancer Radiother. 2010 Nov;14 Suppl 1:S34-42. doi: 10.1016/S1278-3218(10)70006-8. Cancer Radiother. 2010. PMID: 21129668 French.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C; PRODIGE 59-FFCD 1707-DURIGAST Investigators/Collaborators. Tougeron D, et al. JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0207. Online ahead of print. JAMA Oncol. 2024. PMID: 38573643
Metastases-directed radiotherapy in castration resistant oligo metastatic prostate cancer: A multicentric retrospective study from the French group COLib.
Chamois J, Septans AL, Schipman B, Gross E, Blanchard N, Passerat V, Debelleix C, Hemery CG, Latorzeff I, Pointreau Y. Chamois J, et al. Among authors: debelleix c. Clin Transl Radiat Oncol. 2024 Mar 17;46:100762. doi: 10.1016/j.ctro.2024.100762. eCollection 2024 May. Clin Transl Radiat Oncol. 2024. PMID: 38572302 Free PMC article.
Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis.
Yuste C, Passerat V, Calais G, Schipman B, Vaugier L, Paumier A, Huertas A, Hemery CG, Debelleix C, Chamois J, Blanchard N, Septans AL, Pointreau Y. Yuste C, et al. Among authors: debelleix c. Clin Transl Radiat Oncol. 2023 Dec 7;45:100708. doi: 10.1016/j.ctro.2023.100708. eCollection 2024 Mar. Clin Transl Radiat Oncol. 2023. PMID: 38162282 Free PMC article.